Pharmaids Pharmaceuticals opened higher at ₹29.31, compared with its previous close of ₹29.17. In the last trading session on 12 Nov 2026, the stock traded between ₹29.00 and ₹29.97, with an average traded price of ₹29.44. It showed an upward intraday trend.
An investment of ₹10,000 made 5 years ago in Pharmaids Pharmaceuticals is now worth
₹ 17,664.00
Giving a profit of
₹ 7,664.00 (76.64%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+0.77 (+2.64%)
Day High
₹29.97
Day Low
₹29.00
Day Open
₹29.31
Prev Close
₹29.17
Volume
3,966
Value Traded
₹0.01 Cr
1W Return
2.08%
1M Return
-2.82%
3M Return
-11.94%
6M Return
-3.98%
1Y Return
-38.87%
Market Cap (₹ Cr.)
106
PE Ratio
-23.30
PB Ratio
2.16
Dividend Yield
-
ROE
-24.31%
ROCE
-20.25%
Book Value (₹)
13.51
Face Value (₹)
10.00
EPS (TTM)
-0.60
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
2.08%
6 Weeks
-
1 Month
-2.82%
3 Months
-11.94%
9 Months
-23.13%
Pharmaids Q2FY27 Results: Net loss narrows to ₹112 lakh
Standalone net loss narrowed to ₹112.19 lakh in Q2FY27 from ₹165.23 lakh in Q2FY26. Standalone revenue from operations fell to ₹106.02 lakh from ₹596.55 lakh YoY. Consolidated net loss reduced to ₹180.91 lakh from ₹322.94 lakh in the prior year. Cash and cash equivalents dropped to ₹0.25 lakh on a standalone basis.
YesterdayPharmaids Pharmaceuticals files complaint over ₹2.62 Cr cheque dishonour
Pharmaids Pharmaceuticals filed complaints against Anugraha Chemicals for cheque dishonour. Total claim amount is ₹2.62 crore comprising two cheques issued in July 2026. Dispute stems from unpaid dues following Pharmaids' exit from partnership in the firm. Legal action filed at Bengaluru court under Bharatiya Nagarik Suraksha Sanhita.
1mo agoPharmaids Pharmaceuticals schedules 37th AGM for September 11 via VC
Pharmaids Pharmaceuticals Limited is holding its 37th AGM on September 11, 2026, via video conferencing. E-voting will be available from September 8 to September 10, 2026, for shareholders on record as of September 4. The company has complied with SEBI regulations by providing electronic access to the annual report and notice.
2mo agoPharmaids Q4 Results: Revenue up 43% YoY, Loss widens to ₹115.7 crore
Pharmaids Pharmaceuticals reported FY26 consolidated revenue of ₹278.8 crore, up 43% YoY, with a net loss of ₹115.7 crore. Key events include the exit from Anugraha Chemicals and sale of land to a promoter for ₹19.4 crore. No dividend was declared.
2mo agoPharmaids Pharmaceuticals appoints internal auditor for FY 2026-27
Pharmaids Pharmaceuticals Limited appointed M/s. V Mahendra & Associates Chartered Accountants as internal auditor for FY 2026-27, approved by the Board on June 30, 2026. The firm has over 23 years of experience in compliance and internal controls. The disclosure was made under SEBI Regulation 30.
4mo agoPharmaids Pharmaceuticals VP resigns citing personal reasons
Pharmaids Pharmaceuticals Limited accepted the resignation of Dr. Jagadeesh M N as Vice President – Discovery Services effective June 25, 2026, due to personal reasons. The disclosure was filed with BSE under Regulation 30 of the SEBI Listing Regulations.
4mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,896.40 | +0.60% | ₹4,55,009.88 | 41.20 | +9.49% | |
| ₹11,503.00 | +0.16% | ₹3,05,368.51 | 90.40 | +76.43% | |
| ₹4,686.00 | -0.87% | ₹1,78,240.38 | 85.50 | +22.52% | |
| ₹2,432.80 | +1.37% | ₹1,31,447.16 | 97.10 | +145.92% | |
| ₹1,204.50 | -0.12% | ₹1,20,149.34 | 28.00 | +26.60% | |
| ₹1,388.50 | +0.14% | ₹1,15,895.36 | 42.00 | +12.92% | |
| ₹1,408.80 | +0.04% | ₹1,13,811.10 | 39.90 | -7.27% | |
| ₹2,665.50 | +1.02% | ₹1,10,097.17 | 48.10 | +17.42% | |
| ₹1,814.80 | +0.42% | ₹1,04,419.58 | 26.00 | +53.33% | |
| ₹2,019.00 | +0.20% | ₹92,326.85 | 17.60 | -0.73% | |
| ₹2,641.50 | -0.69% | ₹74,549.65 | 51.60 | +42.95% | |
| ₹5,182.50 | -2.25% | ₹61,964.56 | 30.50 | -10.14% |
An investment of ₹10,000 made 5 years ago in Pharmaids Pharmaceuticals is now worth
₹ 17,664.00
Giving a profit of
₹ 7,664.00 (76.64%)
Note: Past profits do not guarantee future returns.
